Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

CATX

Perspective Therapeutics (CATX)

Perspective Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:AMEX:CATX
일자시간출처헤드라인심볼기업
2024/05/1520:00GlobeNewswire Inc.Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 ResultsAMEX:CATXPerspective Therapeutics Inc
2024/05/0320:00GlobeNewswire Inc.Perspective Therapeutics to Participate at Upcoming May Investor ConferencesAMEX:CATXPerspective Therapeutics Inc
2024/05/0220:00GlobeNewswire Inc.Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial ResultsAMEX:CATXPerspective Therapeutics Inc
2024/04/3020:00GlobeNewswire Inc.Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETsAMEX:CATXPerspective Therapeutics Inc
2024/04/0821:00GlobeNewswire Inc.Perspective Therapeutics to Participate at Upcoming April Investor ConferencesAMEX:CATXPerspective Therapeutics Inc
2024/03/2820:30GlobeNewswire Inc.Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial ResultsAMEX:CATXPerspective Therapeutics Inc
2024/03/1821:00GlobeNewswire Inc.Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic MelanomaAMEX:CATXPerspective Therapeutics Inc
2024/03/1121:00GlobeNewswire Inc.Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024AMEX:CATXPerspective Therapeutics Inc
2024/03/0522:00GlobeNewswire Inc.Perspective Therapeutics Acquires CGMP-Compliant Manufacturing FacilityAMEX:CATXPerspective Therapeutics Inc
2024/03/0423:45GlobeNewswire Inc.Perspective Therapeutics Announces $87.4 Million Private PlacementAMEX:CATXPerspective Therapeutics Inc
2024/02/2622:00GlobeNewswire Inc.Perspective Therapeutics to Participate at Upcoming Investor ConferencesAMEX:CATXPerspective Therapeutics Inc
2024/02/1222:00GlobeNewswire Inc.Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceAMEX:CATXPerspective Therapeutics Inc
2024/01/2306:05GlobeNewswire Inc.Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private PlacementAMEX:CATXPerspective Therapeutics Inc
2024/01/1821:00GlobeNewswire Inc.Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private PlacementAMEX:CATXPerspective Therapeutics Inc
2024/01/1806:05GlobeNewswire Inc.Perspective Therapeutics Announces Proposed Public OfferingAMEX:CATXPerspective Therapeutics Inc
2024/01/1722:00GlobeNewswire Inc.Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01AMEX:CATXPerspective Therapeutics Inc
2024/01/1006:10AllPennyStocks.comAnother Healthcare Stock Stealing The ShowAMEX:CATXPerspective Therapeutics Inc
2024/01/0922:00GlobeNewswire Inc.Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective TherapeuticsAMEX:CATXPerspective Therapeutics Inc
2024/01/0922:00GlobeNewswire Inc.Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing CapabilityAMEX:CATXPerspective Therapeutics Inc
2024/01/0522:00GlobeNewswire Inc.Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer TreatmentAMEX:CATXPerspective Therapeutics Inc
2024/01/0222:00GlobeNewswire Inc.Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceAMEX:CATXPerspective Therapeutics Inc
2023/12/1222:00GlobeNewswire Inc.Perspective Therapeutics Divests Brachytherapy BusinessAMEX:CATXPerspective Therapeutics Inc
2023/12/0722:00GlobeNewswire Inc.Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine TumorsAMEX:CATXPerspective Therapeutics Inc
2023/06/1505:46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:CATXPerspective Therapeutics Inc
2023/06/1505:42Edgar (US Regulatory)Specialized Disclosure Report (sd)AMEX:CATXPerspective Therapeutics Inc
2023/06/0705:35Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:CATXPerspective Therapeutics Inc
2023/05/1606:23Edgar (US Regulatory)Quarterly Report (10-q)AMEX:CATXPerspective Therapeutics Inc
2023/05/1606:16Edgar (US Regulatory)Current Report Filing (8-k)AMEX:CATXPerspective Therapeutics Inc
2023/05/0206:04Edgar (US Regulatory)Annual Transition Report (10-kt)AMEX:CATXPerspective Therapeutics Inc
2023/04/2006:53Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:CATXPerspective Therapeutics Inc
 검색 관련기사 보기:AMEX:CATX